Development of Piribedil Solid Lipid Nanoparticles Incorporated in Nasal In-situ Gel by DoE

Abstract

Solid lipid nanoparticles (SLNs) are a promising drug delivery platform for regulated, controlled release and targeted distribution. The current study aimed to prepare stable piribedil-loaded nanoparticles with optimized intranasal delivery. Using A 3-factor, 3-level Box-Behnken design (BBD), regression analysis, and 3-D response surface methodology (RSM) plots, the influence of independent process variables, like drug-to-lipid ratio, conc of poloxamer 407 and conc of glyceryl monostearate, on dependent variables, such as entrapment effectiveness and the vesicle size of piribedil SLNs, was assessed. The formulated SLNs exhibit a spherical morphology and exhibit a low degree of crystallinity. The nanoformulation exhibited a higher release of medication compared to the piribedil suspension. The 12-hour drug release demonstrated the use of controlled-release medicine delivery. By adding hyaluronic acid to intranasal formulations, the average particle size (PS), polydispersity index (PDI), and zeta potential (ZP) were all considerably raised. The saturation solubility of nanosized piribedil was 7.1 times that of the unprocessed medication. The nanosized formulation had a greater flux than the pure piribedil reference sample. R3 had a permeability coefficient (Kp) of 0.022 cm h−1, while F3 had a higher value of 0.108 cm h−1. Compared to R3, F3 diffused 15.68 µg cm−2 of the drug in the first 15 minutes. Because of their large surface area, nanoparticles enhance diffusion. This study reveals that Piribedil-containing SLNs may be more therapeutic than traditional formulations.